Illumina Inc Stock Price, News & Analysis

Illumina (NASDAQ: ILMN) has unveiled PromoterAI, a groundbreaking AI algorithm that accurately identifies pathogenic regulatory genetic variants in noncoding regions of the human genome. According to a study published in Science, this technology discovered regulatory variants in promoter segments that contribute up to 6% of genetic causes of rare diseases.

PromoterAI analyzes noncoding promoter regions, which are crucial for gene transcription and comprise over 98% of the genome. When combined with whole-genome sequencing (WGS), this AI tool could improve rare disease diagnosis rates, which currently stand at only 30% with exome sequencing. The algorithm, together with Illumina's other AI tools (PrimateAI-3D and SpliceAI), effectively doubles the diagnostic yield compared to using protein-truncating variants alone.

The technology is now available through Illumina Connected Software and DRAGEN™ secondary analysis, with precomputed scores freely available for academic and noncommercial research.

Illumina (NASDAQ: ILMN) announced an expansion of its clinical oncology portfolio with two key developments. First, their TruSight™ (TSO) Comprehensive test, the first FDA-approved distributable comprehensive genomic profiling IVD kit with pan-cancer CDx claims, has gained broad payer reimbursement including Medicare and most commercial health plans. UofL Health became the first customer to implement the test. The test has also received regulatory approval in Japan.

Second, Illumina partnered with Pillar Biosciences to offer Pillar oncoReveal CDx, an IVD kit for detecting genetic variations in 22 genes for solid tumor patients. The test recently received nationwide Medicare coverage, making it accessible to over 66 million Medicare beneficiaries in the US.

Illumina (NASDAQ: ILMN) has announced its participation in the upcoming 41st Annual Bernstein Strategic Decisions Conference. The company's executives will engage in a fireside chat on May 28, 2025, at 11:30 AM Pacific Time (2:30 PM Eastern Time). Investors and interested parties can access the webcast through the Investor Info section on investor.illumina.com. A replay of the presentation will be available on the company's website for a minimum of 30 days following the event.

The dataset will be the largest commercially available clinical multiomic dataset for GLP-1 therapies, incorporating whole-genome sequencing and protein expression profiling of 5,000 samples using Illumina's IPP assay that detects 9,500 human proteins per sample.

This initiative addresses significant market needs, as 1 in 8 adults in the US use GLP-1 receptor agonists, but approximately 40% of Type 2 diabetes patients don't respond effectively to these treatments. The dataset will help identify new indications, biomarkers, and drug targets, particularly for non-responsive patients.

Illumina (NASDAQ: ILMN) and Tempus AI (NASDAQ: TEM) have announced a strategic collaboration to accelerate the clinical adoption of next-generation sequencing tests through AI-driven innovation. The partnership aims to combine Illumina's AI technologies with Tempus's multimodal data platform to enhance genomic algorithms and expand molecular profiling across various disease categories.

The collaboration focuses on developing evidence to standardize comprehensive genomic profiling and molecular testing beyond cancer, extending to cardiology, neurology, and immunology. This builds upon the companies' existing partnership in developing tools and assays for testing needs from preemptive screening through therapy selection.

The initiative addresses the current gap where patients often miss precision medicine benefits due to non-standardized molecular profiling across disease areas and regions. The partnership will leverage data analytics and sequencing technologies to improve patient outcomes and advance precision medicine research.

Illumina (NASDAQ:ILMN) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call and webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.

The earnings discussion will be led by CEO Jacob Thaysen, PhD, and CFO Ankur Dhingra, who will review the company's financial and operating results with analysts, investors, and other interested parties. Participants are advised to join the webcast at least ten minutes before the scheduled start time through Illumina's Investor Info section. A replay will be available on the company's website for a minimum of 30 days following the event.

Illumina (NASDAQ: ILMN) announced significant changes to its Board of Directors. Dr. Scott Gottlieb, who has served on the Board since 2020, has been elected as non-executive Chair. Additionally, Keith Meister, founder and Chief Investment Officer of Corvex Management, will join the Board on March 28, 2025.

Stephen MacMillan, who joined the Board in June 2023, will retire ahead of the upcoming annual shareholder meeting. Dr. Gottlieb expressed commitment to advancing the company's mission and driving profitable growth, while Meister voiced confidence in Illumina's strategy to expand its role in genomics and deliver shareholder value.